Posted by OKU_2220 > 2020-12-15 09:19 | Report Abuse

OKU_2220_GOOD_NEWS

The good news is ....
No matter budget down, goverment collapsed, meteor shower, earthquake le.....

Saudara (OKU_2020_FAKE ), now we are talking about share market wo....
Like this you also scare.....
People like you, please la, play monopoly better la...
Scare here, scare there, mengamuk ke sana, ke sini....


Ha... Ha... Ha...
Like Maslan said... Saya pun binggung la...
Saudara, please la... yiou laugh die me...

Haiz..... lagi saya kesian awak...

Nexgram boleh

Posted by OKU_2220 > 2020-12-15 09:24 | Report Abuse

OKU_2220_GOOD_NEWS

Lagi satu, (8dragon), nama bagus, tapi pun macam ( 8 kecut bolas )
Boleh tukar nama, panggil
(8chicken) lagi cun...

Mahu main saham... tapi macam main siham....

Ha...Ha... Ha..
Kesian..

Posted by 8dragon > 2020-12-15 09:31 | Report Abuse

Kalau PN tumbang, Nexgram akan balik ke paras 1-3 cents sebab contracts semua dibatal untuk kroni PH....

Posted by OKU_2220 > 2020-12-15 09:39 | Report Abuse

OKU_2220_GOOD_NEWS

That why call u 8chicken.... got contract one.. u think new goverment not understanding meh...
No need 1 - 3 sen la... give u free la... see you desperate wannna buy at 1 - 3 sen...

Jatuh standard awak ni,...
Nasib baik saya tak kena awak...

Haiz...
Kesian...

Ha..Ha.. Ha..

Posted by nizarplanet > 2020-12-15 09:45 | Report Abuse

Susah mau pegang lama Bursa kaunter skg. Sikit punya isu terus jatuh.
Baru 5% hijau esk sudah 10% merahhhh...

Posted by OKU_2020 > 2020-12-15 10:18 | Report Abuse

8dragon@ Kalau PN tumbang, Nexgram akan balik ke paras 1-3 cents sebab contracts semua dibatal untuk kroni PH....
+++++++++
YOOOOO SIFU 8Dragon...

Critical & Dangerous NOWWWWW......
further more this is a Cap Ayam -Holland GN3 ( PN 17 ) Nexgram....

Posted by char1234 > 2020-12-15 11:15 | Report Abuse

too many many shares ...

Posted by jibrilsayang1 > 2020-12-15 11:27 | Report Abuse

Sembang kari

Posted by OKU_2020 > 2020-12-15 14:37 | Report Abuse

btuscy@... yeay, many will suicide later.
14/12/2020 3:03 PM
+++++++++

many edi KENA PREQQQ liao....No way out

Kena PREQQ Boy2511 edi give up & Cabutttt.....

Posted by papaya > 2020-12-15 14:46 | Report Abuse

sudah ramai fed up and frust menonggeng.....kikikikikih

jual ....jangan tak jual.......kikikikikikikih

rewards only for patient traders......kikikikikih

Posted by OKU_2020 > 2020-12-15 15:25 |

Post removed.Why?

Posted by papaya > 2020-12-15 17:02 | Report Abuse

sudah ramai fed up and frust menonggeng.....kikikikikih

jual ....jangan tak jual.......kikikikikikikih

rewards only for patient traders......kikikikikih
15/12/2020 2:46 PM
++++++

smart MZM2511 oledi RUNNNNNNNNN for his life.....
those remained here risk of left with tulang tongkeng....
15/12/2020 3:25 PM

----------------------------------------------------------------

will see.......kikikikikih

Posted by kangcs > 2020-12-15 17:09 | Report Abuse

0.055 ok la

Posted by papaya > 2020-12-15 19:27 | Report Abuse

https://malaysiastock.biz/Company-Announcement.aspx?id=1281817

Posted by papaya > 2020-12-15 19:28 | Report Abuse

NEXGRAM HOLDINGS BERHAD (“NEXGRAM” OR “COMPANY”)
REPLY TO QUERY LETTER FROM BURSA MALAYSIA SECURITIES BERHAD DATED 14
DECEMBER 2020 (REF : IQL-14122020-00001)
SUBJECT : OTHERS
DESCRIPTION : NEXGRAM HOLDINGS BERHAD (“NEXGRAM” OR “THE
COMPANY”)
MASTER STRATEGIC JOINT VENTURE AGREEMENT
BETWEEN VACCINES LAB SDN BHD (“VACCINESLAB”), A
WHOLLY-OWNED SUBSIDIARY OF NEXGRAM HOLDINGS
BERHAD, WITH RAFARMA PHARMACEUTICALS INC.
(“RAFARMA”)
The Company’s announcement dated 10 December 2020 (“Announcement”) and the query
letter from Bursa Malaysia Securities Berhad dated 14 December 2020 (Ref : IQL-14122020-
00001) in relation to the Master Strategic Joint Venture Agreement (“Agreement”) refer.
Unless otherwise stated, the terms used in this announcement shall have the same meaning
as defined in the Announcement.
The Board of Directors of Nexgram wishes to announce the following additional information
as required in Query:
1. The proposed principal activities of the joint venture company (“JVC”)
The principal activities of the JVC are sourcing and distributing of vaccines to ASEAN
markets, with option to build up vaccine manufacturing plant in Indonesia.
2. The capital and investment outlay by VaccinesLab in the JVC, its sources of
funding and the breakdown.
The joint venture plant would cost approximately USD250 million for phase 1, and in
principle is fully funded by major shareholder Rafarma and its group of investors to be
identified. Details of pre-operation cost is currently under negotiation.
3. The relevant regulatory approvals required to be obtained by the JVC before it
can commence its operations.
The main law providing for manufacturing, licensing and sale of pharmaceutical
products is the Regulation No. 1010/XI/2008 on Registration of Medicines issued by
the Ministry of Health of Indonesia. All activities of pharmaceutical companies
registered in Indonesia are supervised by the Food and Medicine Supervisory Board
(“BPOM”). The Group through subsidiary PT NDS Global Teknologi in Indonesia shall
engage professional specialise in feasibility study and registration studies with BPOM.
4. The equity interest to be subscribed by VaccineLabs in the JVC.
Except Group existing operation cost (Opex), the Group shall allocate approximately
USD1 million and pre-operation cost for feasibility study and registration through
internal generated fund. Capital Expenditure (Capex) is as per Q2 above, currently
under negotiation.
5. Please provide further information on RAFARMA including the shareholders,
board of directors, senior management and listing status (if RAFARMA is listed).
The main shareholder is IIya Shpurov who holds 91.3% of RAFARMA. The board of
directors are:-
i. Ilya Shpurov;
ii. Srecko Bojt; and
iii. Vladimir G. Dolgolenko (who is also the CEO of RAFARMA).
6. Pertaining to the Parties’ desire to develop and conduct the Clinical Trial and
invest in the Vaccine Plant, please clarify how does RAFARMA intend to strive
for access to the Covid-19 vaccines for use/test/distribution, i.e. whether
RAFARMA intends to source for the said vaccines or intends to develop the said
vaccines. To also clarify the current stage of acquisition/development of the
Covid-19 vaccines.
According to RAFARMA, they are working with one of a Russian national
pharmaceutical pioneer established since 1959 with strong research and development
team for vaccine research and development in the long-term; where as its existing
network with Russian government and European pharmaceutical companies in terms
of sourcing, distribution and conduct clinical trial for established vaccines in the shortterm. Details of the plan are currently under discussion between RAFARMA and
VaccinesLab advisors.
7. Please clarify what are the expected or agreed milestones with regard to Clinical
Trial and Vaccine Plant.
Disclosable long-term milestones are as per Q6 above. Currently the companies had
formed regular studies and evaluation discussions team between RAFARMA and
VaccinesLab advisors on WHO’s listed Covid-19 vaccine clinical trial results especially
in terms of safety and efficacy, as well as comparing the research with Russian
vaccines currently under various stages of studies, including phase 1 to 3 clinical trials.
The team shall propose to VaccinesLab the relevant vaccines deem suitable for
ASEAN market in line with WHO updates and standards.
8. Please clarify the source of funding and/or arrangement through which
RAFARMA intends to secure the USD1 billion investment.
The joint venture plant in principle is fully funded by major shareholder RAFARMA and
its group of investors to be identified. Details of the funding structure is currently under
midst of discussion.

Posted by OKU_2020 > 2020-12-15 19:39 | Report Abuse

@ papaya.....
BURSA " SMELLS A RAT " on This Cap Ayam Nexgram....
DANGEROUSSS Tomorrow.....
# NEXGRAM IS IN HOT SOUP. NOWWW....

Posted by OKU_2220 > 2020-12-15 19:49 | Report Abuse

OKU_222)_GOOD_NEWS

OKU_2020 :
DANGEROUSSS Tomorrow.....

Why ? Tomorrow still got meteor showers... or eathquake... or Budget not approve again..
Ha..Ha.. Ha..

***********************
OKU_2020 :
NEXGRAM IS IN HOT SOUP. NOWWW....

Hot Soup ? Kuey Teow Soup, Mee Soup..
Or you mean plus cap ayam soup ah ...
Ha.. Ha... Ha..

Haiz... Kesian
Can't Help You Rich Again....

Keh ... Keh... Keh....

Posted by jibrilsayang1 > 2020-12-15 20:10 | Report Abuse

Ok la

Posted by OKU0096 > 2020-12-15 20:29 | Report Abuse

ATTACKKKKMMK

ESPECIALLY WARRANT A, B AND C

Posted by TEEXIANX1840 > 2020-12-15 20:57 | Report Abuse

mai pula satu OKU baru.

Posted by Abd Rahim Osman > 2020-12-15 21:20 | Report Abuse

Lama lama kita pun KO

Posted by 8dragon > 2020-12-15 21:21 | Report Abuse

Ini forum adalah untuk orang oku saja, semua komen adalah dari orang cacat akal....

Posted by jibrilsayang1 > 2020-12-15 21:34 | Report Abuse

Haahah.letih lagu ni

Posted by limit_up > 2020-12-15 21:56 | Report Abuse

Sudah mau naik la.
Ozura sudah bertaubat. Tak dispose lagi.

Posted by OKU_2020 > 2020-12-15 23:23 | Report Abuse

Too many quiries from authority/ Bursa means suspicious ...NO good actually.
Smell A Rat ( English Idiom for something is wrong ).

Be Careful with this Cap Ayam Nexgram....as .many edi trapped liao , no way out.
Smell further Bad Quarter result to be out next 2:weeks...Be Prepared !

Posted by OKU_2020 > 2020-12-16 07:24 | Report Abuse

if UMA ( Unusual Market Activity ) is OK -Fine ... but now it is Very Serious Queries from Authority @Bursa....

Many don't realize this Cap Ayam Nexgram Clinically is already GN3 ( PN17)....
NOTE 17 / GUIDANCE NOTE 3
PRACTICE NOTE 17 / GUIDANCE NOTE 3
NEXGRAM HOLDINGS BERHAD ("NEXGRAM" OR "COMPANY")BURSA MALAYSIA

NEXT ? ..Can't rule out this >> .very afraid liao to say this >> Deli****

Posted by OKU_2220 > 2020-12-16 08:09 | Report Abuse

Tuesday 15.12.2020

KUALA LUMPUR: The Dewan Rakyat has passed Budget 2021 despite two attempts for bloc voting called by Opposition lawmakers.

Opposition MPs called for bloc voting at the committee stage and after the third reading for Budget 2021, with 111 MPs voting aye and 108 nay in both instances. Only one MP was absent from voting.

The bloc vote was called by Datuk Mahfuz Omar (PH-Pokok Sena) after Finance Minister Tengku Datuk Seri Tengku Zafrul Abdul Aziz gave a third reading on Budget 2021 in Parliament on Tuesday (Dec 15).

Budget 2021, at RM322.5bil, is the largest budget in Malaysian history.

Posted by limit_up > 2020-12-16 09:10 | Report Abuse

Mari mari beli, Ozura sudah tak ada kacau.
Kasi Nexgram limit up...

Posted by limit_up > 2020-12-16 09:15 | Report Abuse

Gogogo

Posted by 4jun2020 > 2020-12-16 09:17 | Report Abuse

still on going sideway....so long alredy..haha

Posted by OKU_2020 > 2020-12-16 09:20 | Report Abuse

Ozura edi smelled A RAT......
smart MZM2511 edi fed up - give up >> Cabutttt liao...

with so long list of queries from Authority@Bursa ...Be prepared my frens..!!

English 101 >> Smell A Rat ?...to recognize that something is not as it appears to be or that something dishonest is happening:

Posted by limit_up > 2020-12-16 09:23 | Report Abuse

No more ppl disposing.
Ozura also stop.
Contra player all cabut liao.

Now is time for Nexgram to rise.
Gogogo limit up...

Posted by OKU_2020 > 2020-12-16 09:44 | Report Abuse

Hello....keep on disposing@off loading @ 5 sen every day.....eye OK ?...

Posted by OKU_2020 > 2020-12-16 09:45 | Report Abuse

this trend >> anytime 4.5 sen

Posted by OKU_2220 > 2020-12-16 09:55 | Report Abuse

FM: Kerajaan Tiada Rancangan Perkenal Semula, Cukai Barang Dan Perkhidmatan (GST) (News)

Kerajaan tiada sebarang keputusan yang akan diambil berkenaan kemungkinan pelaksanaan semula Cukai Barang dan Perkhidmatan (GST) dalam keadaan pandemik COVID-19 dan sehingga keadaan ekonomi pulih.

Menteri Kewangan, Tengku Datuk Seri Zafrul Abdul Aziz, berkata keutamaan pada masa ini adalah menyokong usaha memerangi penularan COVID-19, melindungi rakyat dan menyokong perniagaan.

Bagaimanapun beliau berkata, kerajaan sedang menjalankan kajian dan mendapatkan pandangan serta maklum balas pelbagai pihak berkepentingan mengenai kesesuaian untuk melaksanakan apa-apa model cukai kepenggunaan dengan mengambil kira semua aspek termasuk kelemahan sistem cukai jualan dan cukai perkhidmatan sekarang, serta kelemahan sistem GST terdahulu.

"Kajian ini akan meliputi kesan ke atas ekonomi, kos sara hidup, kesan cukai ke atas harga barang serta keupayaan menangani kegiatan ekonomi gelap.

"Sebarang sistem cukai, sama ada ditambah baik atau baharu, perlu bersifat mudah ditadbir dan tidak meningkatkan kos perniagaan di samping dapat mengukuhkan kedudukan fiskal negara," katanya dalam jawapan bertulis di Dewan Rakyat hari ini,

Beliau berkata demikian bagi menjawab pertanyaan Ling Chai Yew (PH-DAP) sama ada kerajaan mempunyai rancangan untuk mengembalikan sistem cukai GST serta kesannya ke atas rakyat berpendapatan rendah dan impak terhadap ekonomi negara.

https://www.bharian.com.my/berita/nasional/...t-tengku-zafrul

Posted by OKU_2220 > 2020-12-16 09:57 | Report Abuse

Tom Cruise is warning 'Mission Impossible 7' crew members that they will be 'fucking gone' if they break COVID safety protocols again

"No apologies. You can tell it to the people that are losing their fucking homes because our industry is shut down"

Posted by OKU_2220 > 2020-12-16 09:57 | Report Abuse

Only 420 deaths from Jan to Dec. Flu itself kills over 10k per year in Malaysia. Means actually covid is just like a mild flu.

You see there are 86k cases of confirm covid in Malaysia. Pretty sure the hidden and asymptomatic cases are at least 10x more. So fatality rate is under 0.1% in Malaysia. So low, like flu.

You are stupid if you still think that covid is very dangerous....it's just a normal flu-like virus.

Posted by OKU_2020 > 2020-12-16 09:57 | Report Abuse

hmmm...now OZURA PROXY - cousin ..@ remote controlled by Ozura !
seems another OZURA.....

#OZURA2

Posted by OKU_2220 > 2020-12-16 09:58 | Report Abuse

https://www.thestar.com.my/business/busines...is-the-address/

Pavilion Group surprised by better-than-expected response from buyers

DAMANSARA Heights or Bukit Damansara, an exclusive and affluent neighbourhood in Kuala Lumpur, looks set to level up its appeal as being “the place” to work and live in Malaysia with the upcoming Pavilion Damansara Heights development.

At a time when developers are scaling back their projects and offering more affordable range homes, the Pavilion Group, in collaboration with the Canada Pension Plan Investment Board (CPPIB), is bucking the trend with the mixed integrated development – which has been wooing affluent buyers and investors alike.

Slowdown or not, the key to success in the property market is to be able to offer customers what they want, says 1Pavilion Property Consultancy Sdn Bhd sales and marketing director Datuk Tracey Lai.

“The vision for Pavilion Damansara Heights was that Damansara Heights is ‘the address’ and there have not been many developments in this location. This is because there’s very limited landbank in the area,” she tells StarBizWeek.

Lai says a unique selling point of the project is that it faces the Sprint highway and sits between two MRT stations.

“So we have a very strong basic foundation for the project. We already have the connectivity – it’s two stops from KL Sentral. It’s unique and I don’t think there will be another similar kind of development coming up anywhere near it with this kind of size.”

The 16-acre Pavilion Damansara Heights project, which will have a gross development value of RM9bil, will have a total of 10 office blocks, of which eight are en bloc sales, and two on strata basis. Seven of the en bloc sales have already been formally acquired.

“These are boutique blocks. The planning is that offices are part of the support element. For en bloc buyers, they get full visibility. Because of its unique position, it is advertising itself as they can be seen and they are also accessible. So these have been key selling points for the corporate towers.”

In recent years, the local office property market, especially within the Klang Valley, has been experiencing a glut.

According to the National Property Information Centre’s property market report last year, Kuala Lumpur office building completions stood at 320,643 sq m, but the take-up rate was only 24,646 sq m.

Pavilion Damansara Heights will have about 1.5 million sq ft of office space, a third of which will be in the last and highest block. All eight blocks will be acquired by corporate companies or corporate figures. The smallest is an 11-storey block with a net lettable area of 75,000 sq ft.

The development is part of the larger Pusat Bandar Damansara, which has a 46-acre foot print which the Pavilion Group shares with a couple of other developers.

Lai says an added appeal to the corporate towers within Pavilion Damansara Heights is that the buildings are designed for BCA Green Mark accreditation. This is a green building rating system that evaluates a building for its environmental impact and performance.

The rating provides a comprehensive framework to promote sustainable design, construction and operations practices in buildings, says Lai,

“The buildings are also designed for MSC status. With this (BCA and MSC) dual compliance, rental yield and appreciation is generally higher. This is however only achievable for newer built projects,” she says.

Lai says the integrated development, which would also feature a retail component, will be complemented by the offices.

The Pavilion Damansara Heights development will also have about 1,300 residential units, with sizes ranging from 600 sq ft to 2,800 sq ft.

Lai says the interest so far for its residential blocks has been in the larger units, which again bucks the trend because other developers have reported interest in smaller units of about 1,000 sq ft and below.

“By the end of 2017, we will be launching two of the residential towers consisting of 746 units. We anticipate at least 85% take-up rate by the end of the year. We project the first to sell will be the bigger units as we see many people moving out from their bungalows.”

Prices average RM1,800 per sq ft and close to 2,500 have registered their interest, says Lai.

“The best thing to invest in currently is property. With the depreciation of the ringgit, it’s expensive to purchase overseas. So buying locally is the best option right now.

“And Pusat Bandar Damansara is the perfect fit. I don’t think you’ll find anything quite like it now.”

Posted by OKU_2220 > 2020-12-16 10:05 | Report Abuse

Start today, you can post what ever you like....
Post is freedom..

Kesian....
Ha... Ha.. Ha...

For real / serious investor, Kindly go to : telegram / discussion
Thank you..

<< NXGRAM CLUB >>

Posted by OKU_2020 > 2020-12-16 10:05 | Report Abuse

looks like this have the " SAME DNA " with OZURA
hmmm >>....#OZURA2

Posted by manbp2000 > 2020-12-16 10:09 | Report Abuse

On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price could begin climbing to more fair and reasonable market valuations, as compared to more well known peers.

Who is Rafarma Pharmaceuticals?

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company, formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.

Meet Biocogency

Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.

A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC Kraspharma, which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.

Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the government of the Russian Federation and sold through multiple international markets.

What Biocogency Adds to Rafarma

This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.

The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia’s largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of products for medical equipment and packaging for medical and pharmaceutical products, are both steeped in corporate history going back half a century or more in Russia.

Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.

What’s in it for RAFA? An Immediate Spike in Revenue and Profits

The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.

Those results are going to get an immediate shot of adrenaline

Posted by OKU_2020 > 2020-12-16 10:25 | Report Abuse

hmmm....now we got to live with " OZURA2 "....!!

what say U , MZM2511....seems edi Give UP - Cabuttt & NOW in Hiding !

Posted by OKU_2220 > 2020-12-16 10:26 | Report Abuse

Start today, you can post what ever you like....
Post is freedom..

Kesian....
Ha... Ha.. Ha...

For real / serious investor, Kindly go to : telegram / discussion
Thank you..

<< NXGRAM CLUB >>

Posted by OKU_2020 > 2020-12-16 10:31 | Report Abuse

whatt....what ..Telegram ?..sound like in the Filim Gilfren...malay classic P Ramlee
olang kampong - my Grandma time 1950'S

Posted by OKU_2020 > 2020-12-16 10:31 | Report Abuse

Beware....OZURA2

Posted by OKU_2220 > 2020-12-16 10:32 | Report Abuse

Start today, you can post what ever you like....
Post is freedom..

Kesian....
Ha... Ha.. Ha...

For real / serious investor, Kindly go to : telegram / discussion
Thank you..

<< NXGRAM CLUB >>

Posted by Abd Rahim Osman > 2020-12-16 10:44 | Report Abuse

Fening lalat

Posted by OKU_2020 > 2020-12-16 10:44 | Report Abuse

seems that >>
" terlepas mulut harimau masuk mulut buaya "

" let go of the tiger's mouth@OZURA into the crocodile's mouth@OZURA 2 "

Posted by OKU_2220 > 2020-12-16 10:45 | Report Abuse

Start today, you can post what ever you like....
Post is freedom..

Kesian....
Ha... Ha.. Ha...

For real / serious investor, Kindly go to : telegram / discussion
Thank you..

<< NXGRAM CLUB >>